Be part of our Research

News

Sharing research, developing partnerships

November 14th 2017

Censo Biotechnologies has been on the exhibition trail over the last few weeks attending some key industry events to present posters, highlight the company's iPSC services and to meet up with colleagues and potential partners.

Read
News

Human iPSC derived Microglia-like cells

October 19th 2017

Microglia are the tissue resident macrophage of the brain. Our poster, presented at ELRIG Drug Discovery 2017, describes Censo’s human Microglia-like cell characterisation and how these cells, which are available for clients, can be a useful tool in drug discovery projects.

Read
News

Presentation: Humanized Phenotypic Screening Platform for Chronic Pain

August 21st 2017

In case you missed our Webinar... We now have a presentation available, in conjunction with Cellectricon, of a first in kind fully humanized screening platform that enables clients to make the best decisions on which compounds to advance to the clinic.

Read
News

A positive experience for summer interns at Censo Biotechnologies

July 13th 2017

At the end of May, we welcomed three recruits on our summer intern programme. After six weeks, we are pleased to hear such encouraging comments from the students and asked them to share some of their highlights.

Read
News

Censo Biotechnologies and Leeds University collaborate to create stem cells from cancer tissue

July 5th 2017

Scientists at Censo Biotechnologies are developing a new approach to cancer research using stem cell technology. In collaboration with the Leeds Institute of Cancer and Pathology at the University of Leeds, Censo will create induced pluripotent stem cells (iPSCs) from brain tumours removed from patients as part of their clinical treatment.

Read
News

Censo Biotechnologies announces strategic collaboration with Evotec AG to expand iPSC drug discovery

June 28th 2017

Censo Biotechnologies Ltd. (“Censo”) announced today that it will be collaborating with Evotec AG (Frankfurt Stock Exchange: EVT) to source and provide patient-derived induced pluripotent stem cells (“iPSC”) to support Evotec’s drug discovery iPSC platform.  

Read
News

Scalability of the iPSC technology for future drug discovery & therapy

June 22nd 2017

The EBiSC consortium invites you to the Workshop on "Scalability of the iPSC technology for future drug discovery & therapy" which will take place on 2-3 November 2017 at Fraunhofer-Forum in Berlin.

Read
News

Phenotypic profiling and iron overload of sensory neurons derived from Friedrich’s ataxi iPSC

June 12th 2017

Our poster 'Phenotypic profiling and iron overload of sensory neurons derived from Friedrich’s ataxi iPSC' will be presented at ISSCR 2017, the International Society for Stem Cell Research annual meeting in Boston, on Wednesday 14th June at 7.30pm by Rachel Steeg, PHD, Project Lead.

Read
News

Nature Methods publish Application Note - A humanized phenotypic screening platform for chronic pain

June 1st 2017

Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess® Elektra screening system.

Read
News

Launch of Censo Biotechnologies summer intern programme

May 22nd 2017

Censo Biotechnologies is delighted to welcome three recruits for its summer intern programme. Each recruit has been selected from the MSc course in Regenerative Medicine (Clinical and Industrial Delivery) run by Dr Paul Travers at the Scottish Centre for Regenerative Medicine.

Read
News